Comparative Pharmacology
Head-to-head clinical analysis: DEAPRIL ST versus VASOTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEAPRIL ST versus VASOTEC.
DEAPRIL-ST vs VASOTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme (ACE) inhibitor. Inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Enalaprilat, the active metabolite of enalapril, competitively inhibits angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II. This reduces vasoconstriction, aldosterone secretion, and sodium reabsorption, leading to decreased blood pressure and afterload.
Oral: 2.5 mg twice daily, titrated up to 5 mg twice daily as tolerated. Maximum dose: 10 mg daily.
2.5 to 10 mg orally twice daily; initial dose 5 mg once daily; titrate based on blood pressure response; maximum 40 mg/day.
None Documented
None Documented
8-10 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Terminal half-life of enalaprilat is 35-38 hours, with multiple-dose half-life ~11 hours due to prolonged terminal phase; clinical context: once-daily dosing achieves steady-state in 3-4 days.
Renal (90% as unchanged drug), biliary/fecal (10%)
Renal: 60-70% as enalaprilat; fecal: 20-30% as enalaprilat; biliary: minor (<10%).
Category C
Category C
ACE Inhibitor
ACE Inhibitor